Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014

Benoît Henry (1, 2) , Matthieu Revest (3) , Nathalie Dournon (2) , Loïc Epelboin (2, 1) , Guillaume Mellon (2) , Guillaume Bellaud (2) , Pierre Mordant (4) , Damien Le Dû (5) , Nicolas Véziris (6, 2, 1, 2) , Christine Bernard (2, 2) , Sébastien Morel (2, 1) , Stéphane Jauréguiberry (2, 6) , Christian Michelet (7, 3) , François Bricaire (2, 1) , Pierre Tattevin (8, 9, 3) , Éric Caumes (2, 1)

1 UPMC - Université Pierre et Marie Curie - Paris 6
2 CHU Pitié-Salpêtrière [AP-HP]
3 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
4 HEGP - Hôpital Européen Georges Pompidou [APHP]
5 CHU Bligny
6 CIMI - Centre d'Immunologie et de Maladies Infectieuses
7 Irset - Institut de recherche en santé, environnement et travail
8 Fonction, structure et inactivation d'ARN bactériens
9 CIC - Centre d'Investigation Clinique [Rennes]

We report 20 cases of extensively drug-resistant tuberculosis managed in France. Treatment was individualized and included bedaquiline and linezolid for most patients and surgery in 8 patients. At last follow-up (22 months), 19 patients had achieved conversion from positive to negative on culture testing. These promising results of comprehensive management obtained in a small series deserve confirmation.

Mots clés: outcome; antimicrobial resistance; MDR TB; multidrug-resistant tuberculosis; XDR TB; TB; tuberculosis; extensively drug-resistant tuberculosis; France; thoracic surgery; bedaquiline; bacteria; tuberculosis and other mycobacteria

Domaines: Médecine humaine et pathologie

Benoît Henry, Matthieu Revest, Nathalie Dournon, Loïc Epelboin, Guillaume Mellon, et al.. Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014. Emerging Infectious Diseases, 2016, 22 (3), pp.518-521. ⟨10.3201/eid2203.151130⟩. ⟨hal-01294307⟩